DAPAGLIFLOZIN AND SAXAGLIPTIN — MSN, approved 2026-04-06 (ANDA211533).
789 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.